This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drexler, J. F.
Right arrow Articles by Drosten, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drexler, J. F.
Right arrow Articles by Drosten, C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 2007, p. 2061-2063, Vol. 45, No. 6
0095-1137/07/$08.00+0     doi:10.1128/JCM.00136-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Rates of and Reasons for Failure of Commercial Human Immunodeficiency Virus Type 1 Viral Load Assays in Brazil{triangledown}

Jan Felix Drexler,1,2 Luciano Kleber de Souza Luna,1 Celia Pedroso,2 Diana Brasil Pedral-Sampaio,2 Artur T. L. Queiroz,3 Carlos Brites,2 Eduardo M. Netto,2 and Christian Drosten1*

Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany,1 Laboratório de Pesquisa em Infectologia, Hospital Universitário Prof. Edgard Santos, Salvador, Brazil,2 Laboratório de Saúde Avançada, Fiocruz, Salvador, Brazil3

Received 18 January 2007/ Returned for modification 24 February 2007/ Accepted 15 March 2007

We examined failures of commercial human immunodeficiency virus type 1 (HIV-1) viral load assays of 1,195 plasma samples from Brazilian patients. Assay failure was assumed for samples in which the virus was undetectable by commercial assay but which tested positive by real-time reverse transcription-PCR of the HIV-1 long terminal repeat (LTR) region or if the viral load differed by >2 log10 from that determined by LTR assay. Failure rates for Bayer Versant bDNA 3.0, Roche Amplicor Monitor v1.5, and bioMerieux NucliSens QT were 0.68, 0.47, and 4.33%, respectively. NucliSens may be inadequate for use in Brazil.

* Corresponding author. Mailing address: Bernhard Nocht Institute for Tropical Medicine, Clinical Virology Section, Bernhard Nocht Str. 74, 20359 Hamburg, Germany. Phone: 49-40-42818-490. Fax: 49-40-42818-378. E-mail: drosten{at}bni-hamburg.de

{triangledown} Published ahead of print on 28 March 2007.

Journal of Clinical Microbiology, June 2007, p. 2061-2063, Vol. 45, No. 6
0095-1137/07/$08.00+0     doi:10.1128/JCM.00136-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Korn, K., Weissbrich, B., Henke-Gendo, C., Heim, A., Jauer, C. M., Taylor, N., Eberle, J. (2009). Single-Point Mutations Causing More than 100-Fold Underestimation of Human Immunodeficiency Virus Type 1 (HIV-1) Load with the Cobas TaqMan HIV-1 Real-Time PCR Assay. J. Clin. Microbiol. 47: 1238-1240 [Abstract] [Full Text]  
  • Holguin, A., Lopez, M., Molinero, M., Soriano, V. (2008). Performance of Three Commercial Viral Load Assays, Versant Human Immunodeficiency Virus Type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, Testing HIV-1 Non-B Subtypes and Recombinant Variants. J. Clin. Microbiol. 46: 2918-2923 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»